Magle Biopharma

Executive Summary

Magle Biopharma is a Swedish Contract Development and Manufacturing Organization (CDMO) specializing in stem cell-based therapies. As part of the Magle Group, the company offers comprehensive services from process development to GMP manufacturing for both investigational and commercial cell therapies. Founded in 2017 and currently in the pre-clinical stage as a private entity, Magle Biopharma focuses on supporting client innovations with an emphasis on quality and regulatory compliance. With no publicly disclosed pipelines or financials, the company's performance is tied to its ability to secure and execute client contracts in the growing cell therapy CDMO market. Its competitive position relies on expertise in stem cell manufacturing and adherence to stringent regulatory standards.

Upcoming Catalysts (preview)

• Q3 2026New client contract for stem cell therapy manufacturing50% success
• Q2 2026Expansion of GMP manufacturing capacity60% success
• Q4 2026Strategic partnership with a larger biopharma company30% success